EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access · CC BY 4.0

Clinician’s perspectives on gene therapy for Alzheimer’s disease: A qualitative study

Lilly Kelemen iD, Ishika Gupta, Zollie Yavarow iD, Samantha I Smith, Kim G Johnson, Nathan A Boucher iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0307567 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Lilly Kelemen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Duke University, Durham, NC, United States of America. Hauptthemen laut MEDLINE: Alzheimer Disease, Genetic Therapy, Qualitative Research. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We aimed to understand clinician views regarding gene therapy as a future treatment for Alzheimer’s disease (AD) and potential barriers and facilitators to its use.

Methods

We interviewed ten clinicians who treat patients with AD. Clinicians helped design a semi-structured interview including the following domains: establishing understanding, cost/access, quality of life, and religion/spirituality. Transcripts were analyzed by a coding team using descriptive content analysis with inductive approach.

Results

Clinicians identified three main areas of concern: 1) potential clinician and patient understanding of gene therapy and Alzheimer’s disease 2) consideration of inequity (i.e., care access, disease awareness along with education level, family support, trust in care systems); and 3) considerations in decision-making (i.e., religious/spiritual beliefs and method of treatment delivery as a decision-making tools). Discussion and conclusion Findings highlight areas for knowledge-building for patients and clinicians alike. Clinicians must be aware of patient/family educational needs and gaps in their own clinical knowledge before engaging patients/families with new technology. Allowing time for questions is crucial to building rapport and trust.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseGenetic TherapyQualitative ResearchHumansMaleFemaleQuality of LifeMiddle AgedDecision MakingHealth Knowledge, Attitudes, PracticeAdultAttitude of Health Personnel

Autor:innen und Institutionen

  • Duke University, Durham, NC, United States of America.
  • Sanford School of Public Policy, Duke University, Durham, NC, United States of America.
  • Department of Neurology, School of Medicine, Duke University, Durham, NC, United States of America.
  • Division of Geriatric Medicine, School of Medicine, Duke University, Durham, NC, United States of America.

ORCID-Profile: Lilly Kelemen, Zollie Yavarow, Nathan A Boucher

Zitieren

APA

Kelemen, L., Gupta, I., Yavarow, Z., Smith, S. I., Johnson, K. G., & Boucher, N. A. (2024). Clinician’s perspectives on gene therapy for Alzheimer’s disease: A qualitative study. PLOS ONE. https://doi.org/10.1371/journal.pone.0307567

Vancouver

Kelemen L, Gupta I, Yavarow Z, Smith SI, Johnson KG, Boucher NA. Clinician’s perspectives on gene therapy for Alzheimer’s disease: A qualitative study. PLOS ONE. 2024. doi:10.1371/journal.pone.0307567

BibTeX
@article{Kelemen2024,
  author = {Kelemen, Lilly and Gupta, Ishika and Yavarow, Zollie and Smith, Samantha I and Johnson, Kim G and Boucher, Nathan A},
  title = {Clinician’s perspectives on gene therapy for Alzheimer’s disease: A qualitative study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0307567}
}
Kostenlos starten →